PAT and QbD changing powder flow analysis says Freeman

By Gareth Macdonald

- Last updated on GMT

Regulatory demands for ‘in process’ performance data have changed the pharma sector’s approach to materials analysis and enhanced the quality of the drugs it produces according to Freeman Technology.

in-Pharmatechnologist.com spoke with company director of operations Tim Freeman at Interphex 2011 in New York, US, who explained that this change in mindset has had a significant impact on powder flow analysis.

Freeman said that initiatives like PAT and QbD are encouraging industry to consider a material’s characteristics in combination with its intended usage in the manufacturing process, rather than as a separate characteristic.

This change is driving the development of new analysis technologies, Freeman continued, adding that: “The advantage we have in the 21st century is that we can characterise materials… in process relevant ways.

If you have powder in a silo or hopper, rather than just looking at how the density of the powder changes we can measure the sheer strength of the powder to try and simulate the environment the powder is stored in​.”

He added that the ability to quantify powder performance allows drug makers to optimise both formulation development and scale up, improving efficiency and saving time and money.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.